(p < for noninferiority)

Slides:

Advertisements

Similar presentations

Disclosure Statement of Financial Interest

Advertisements

FAME 2 year Objective:To investigate the 2-year outcome of PCI guided by FFR in patients with multivessel CAD. Study:Multicenter, single blind, randomized.

WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.

(p for noninferiority = 0.01)

PRAGUE-18 Trial design: Patients with STEMI undergoing primary PCI were randomized to prasugrel (n = 634) versus ticagrelor (n = 596). Results (p = 0.94)

NORSTENT Trial design: Patients with obstructive coronary artery disease were randomized to a drug-eluting stent (DES) (n = 4,504) versus a bare-metal.

CORAL Trial design: Patients with renal artery stenosis and hypertension or chronic kidney disease were randomized to renal artery stenting (n = 467) vs.

SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.

LONG-DES II Trial Randomized Comparison of the Efficacy of Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent in the Treatment of Long Native Coronary.

TNT: Baseline and final LDL cholesterol levels

Stenting of Coronary Arteries in Non Stress/Benestent Disease

RE-CIRCUIT Trial design: Patients with atrial fibrillation undergoing catheter ablation were randomized to uninterrupted dabigatran 150 mg twice daily.

(p < for group 1 or 2 vs. group 3)

BENEFIT Trial design: Patients with positive serologic tests for T. Cruzi and cardiomyopathy were randomized to benznidazole 300 mg daily for days.

Dual Goals for the Management of Stable Ischemic Heart Disease (SIHD)

AcoArt I Trial design: Patients with femoropopliteal artery disease were randomized to paclitaxel-coated balloon angioplasty (n = 100) vs. standard peripheral.

DANISH Trial design: Patients with nonischemic cardiomyopathy were randomized to ICD implantation (n = 556) versus usual care (n = 560). Results (p = 0.28)

EUCLID Trial design: Patients with peripheral arterial disease (PAD) were randomized to ticagrelor 90 mg twice daily (n = 6,930) vs. clopidogrel 75 mg.

LEVO-CTS Trial design: Patients undergoing cardiac surgery with the use of cardiopulmonary bypass were randomized to infusion of levosimendan 0.2 µg/kg/min.

(p for noninferiority = )

Angiography-guided PCI

BBK II Trial design: Patients undergoing a two-stent approach for a de novo bifurcation lesion were randomized in a 1:1 fashion to either culotte stenting.

EMPA-REG OUTCOME Trial design: Patients with type 2 diabetes mellitus (DM2) at high risk for CV events were randomized to receive in a 1:1:1 fashion either.

End point Elevated PTH Normal PTH p % diameter stenosis < 0.05

EVITA Trial design: Smokers admitted with an acute coronary syndrome were randomized to varenicline 1 mg twice daily (n = 151) vs. placebo (n = 151). Study.

Primary endpoint at 1 year

INOVATE-HF Trial design: Patients with heart failure (HF) were randomized to device implant for vagus nerve stimulation (n = 436) versus optimal medical.

EXCEL Trial design: Patients with unprotected left main disease were randomized to either PCI with an Xience everolimus-eluting stent (EES) or CABG. They.

Losartan vs. Atenolol in Marfan Syndrome

PARTNER 2A Trial design: Intermediate-risk patients with aortic stenosis (STS PROM score 4-8%) were randomized to undergo either TAVR or SAVR, stratified.

Compare-Acute Trial design: STEMI patients undergoing primary PCI were randomized to fractional flow reserve (FFR)-guided complete revascularization (n.

PRECISION Trial design: Patients with arthritis and increased cardiovascular risk were randomized to celecoxib 100 mg twice daily (n = 8,072) vs. ibuprofen.

VALUE Trial design: Hypertensive patients at high cardiovascular risk were randomized to valsartan (n = 7,649) vs. amlodipine (n = 7,596). Results (p =

ANTARCTIC Trial design: Patients with acute coronary syndrome undergoing stenting were randomized to tailored antiplatelet therapy (n = 435) versus conventional.

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

EXCITE ISR Trial design: Participants with femoropopliteal in-stent restenosis were randomized to excimer laser atherectomy + adjunctive angioplasty (n.

SMILE Trial design: NSTEMI patients were randomized to complete revascularization during the index procedure (i.e., 1-stage revascularization; n = 264)

FAMOUS-NSTEMI Trial design: Participants with NSTEMI were randomized to an FFR-guided strategy (n = 176) vs. a coronary angiography-guided strategy (n.

TUXEDO–India Trial design: Patients with type 2 diabetes mellitus (DM2) and coronary artery disease undergoing PCI were randomized to receive Taxus Element.

SUSTAIN-6 Trial design: Patients with DM2 at high risk for CV events were randomized in a 1:1:1:1 fashion to either semaglutide 0.5 mg, semaglutide 1 mg,

PROCAMIO Trial design: Patients with hemodynamically stable wide complex monomorphic tachycardia were randomized 1:1 to either intravenous procainamide.

BASKET-SAVAGE Trial design: Patients with a SVG lesion were randomized to a DES (Taxus Liberte; n = 89) versus a BMS (Liberte; n = 84). All patients were.

BASKET-PROVE II Trial design: Subjects with stable or unstable coronary artery disease undergoing stent implantation were randomized to a biodegradable-polymer.

BAT for HFrEF Trial design: Patients with chronic systolic HF were randomized in a 1:1 fashion to either baroreceptor activation therapy (BAT) or control.

NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.

MACE rate among CAD severity groups (total 0

ALBATROSS Trial design: Patients with MI without heart failure were randomized to an IV bolus of potassium canrenoate 200 mg as early as possible, then.

After Eighty Study Trial design: Elderly patients with non–ST-elevation acute coronary syndrome (NSTE-ACS) were randomized to invasive therapy (n = 229)

FOURIER Trial design: Patients with established cardiovascular disease on statin therapy were randomized to evolocumab 140 mg subcutaneous every 2 weeks.

(p = 0.32 for noninferiority)

AMACING Trial design: Patients with chronic kidney disease undergoing intravascular iodinated contrast administration were randomized to prophylactic hydration.

BRAVO-3 Trial design: Patients undergoing transfemoral TAVR were randomized in a 1:1 fashion to bivalirudin or UFH. They were followed for 30 days. Results.

OSLER Trial design: Patients from five phase 2 trials and seven phase 3 trials with evolocumab were invited to participate in the OSLER extension program,

(p for noninferiority < 0.001)

(p = for noninferiority)

SMART-STRATEGY Trial design: Patients with a bifurcation coronary lesion were randomized to a conservative strategy (n = 128) vs. an aggressive strategy.

Flow diagram for exclusions of trials identified RCT indicates randomized controlled trial Hulten E, et al. Arch Intern Med 2006;166:

ITALIC Trial design: Patients with Xience V (everolimus-eluting stent) PCI were randomized in a 1:1 fashion to receive 6 or 24 months of dual antiplatelet.

SOLID-TIMI 52 Trial design: Participants within 30 days of an acute coronary syndrome (ACS) were randomized to darapladib 160 mg daily (n = 6,504) versus.

DANAMI 3-DEFER Trial design: Patients presenting with STEMI and in whom the operators could establish TIMI 2-3 flow without stenting or those presenting.

Primary safety endpoint

MOMENTUM 3 Trial design: Patients with advanced heart failure were randomized to a centrifugal-flow pump (n = 152) vs. an axial-flow pump (n = 142). Results.

IVUS-XPL Trial design: Patients undergoing drug-eluting stent implantation for long coronary lesions were randomized to IVUS-guided PCI (n = 700) vs. angiography-guided.

(p for noninferiority = 0.01)

MATRIX: Radial vs. Femoral

(p for non-inferiority < 0.001)

NOBLE Trial design: Patients with unprotected left main disease were randomized to either PCI with a drug-eluting stent (DES) (88% biolimus) or CABG. They.

Javier Escaned et al. JCIN 2018;11:

CIRCUS Trial design: Patients with anterior STEMI were randomized to IV cyclosporine 2.5 mg/kg (n = 475) vs. placebo (n = 495) immediately before coronary.

FFR guided deferral of PCI in patients with ACS and stable coronary artery disease (SCAD). FFR guided deferral of PCI in patients with ACS and stable coronary.

Presentation transcript:

(p < 0.001 for noninferiority) DEFINE-FLAIR Trial design: Patients undergoing functional assessment of an indeterminant coronary lesion were randomized to iFR (n = 1,242) versus FFR (n = 1,250). Results (p < 0.001 for noninferiority) All-cause death, MI, or unplanned revasc. at 12 months: 6.8% of the iFR group versus 7.0% of the FFR group (p < 0.001 for noninferiority) Death: 1.9% for iFR vs. 1.1% for FFR MI: 2.7% for iFR vs. 2.4% for FFR Unplanned revascularization: 4.0% for iFR vs. 5.3% for FFR 7.0 6.8 % Conclusions Among patients undergoing functional determination of an indeterminant coronary stenosis for stable or unstable coronary disease, iFR was noninferior to FFR; threshold to revascularize: ≤0.89 for iFR, ≤0.80 for FFR Adverse cardiac events were similar between study groups iFR FFR Davies JE, et al. N Engl J Med 2017;Mar 18:[Epub]